GoLiver Therapeutics Secures Major Funding for GLTX-001
GoLiver Therapeutics is excited to share that it has recently triumphed in the France 2030 initiative, clinching an impressive €1.6 million in funding. This investment is aimed at propelling the development of its innovative biomedicine, GLTX-001, which seeks to provide a new treatment option for severe liver failure through the use of pluripotent stem cells.
Innovative Approach to Severe Liver Diseases
GoLiver Therapeutics is driven by a mission to tackle the escalating liver disease crisis worldwide. With over 800 million people suffering from chronic liver conditions, the company is leading the way in creating a biomedicine that could reduce the reliance on liver transplants, which are the only proven cure for patients facing end-stage liver disease.
The GOCLINICALS Project
The GOCLINICALS project marks a critical advancement in demonstrating the safety, efficacy, and tolerability of GLTX-001. This inventive treatment involves an injectable solution composed of allogeneic liver cells, which can be quickly prepared at the patient’s bedside. Preclinical evidence indicates that GLTX-001 significantly protects liver cells from damage and boosts the organ’s natural ability to regenerate.
Industrial Bioproduction Capabilities
A standout feature of GoLiver Therapeutics is its iMillenium™ manufacturing platform. This cutting-edge facility addresses the difficulties usually associated with producing the vast number of cells needed for effective cell therapy. By utilizing advanced pluripotent stem cell technology, it achieves remarkable yields and cost efficiency. Additionally, the infrastructure enables prompt market deployment, employing bioreactors that are already established in contract manufacturing organizations (CDMOs).
Commitment to Healthcare Innovation
Tuan Huy Nguyen, President of GoLiver Therapeutics, expressed his appreciation for the support from France 2030. He noted that this funding would significantly advance the company's efforts in developing its first advanced cell drug candidate. Nguyen stated, “GLTX-001 will be groundbreaking for patients with liver disease, as impressive preclinical results lay the groundwork for eventual clinical usage.”
Collaborative Efforts and Future Aspirations
To ensure the successful implementation of the GOCLINICALS project, GoLiver Therapeutics plans to leverage its longstanding collaborations with key partners, including the cell and gene therapy unit at Nantes University Hospital and the Paul-Brousse Hospital, one of France’s premier liver transplant centers. This collaboration is not only focused on liver disease but also aims to expand the application of their cell-based therapies to address various medical conditions, broadening their influence in the field of regenerative medicine.
Addressing a Global Health Challenge
Globally, liver failure is responsible for over two million deaths each year, and the supply of donor organs for transplantation is far from meeting demand. By harnessing the regenerative capabilities of patients' own liver cells, GoLiver Therapeutics aims to tackle this pressing medical need with high-quality bioproduced therapies.
About GoLiver Therapeutics
Founded in 2017 as a spin-off from Inserm and Nantes University, GoLiver Therapeutics is poised to become a leader in regenerative medicine by focusing on liver cell regeneration without relying on transplants. The company has garnered multiple accolades, including recognition from the European Union and various national awards, for its pioneering research in healthcare biotechnology.
Frequently Asked Questions
What is GLTX-001?
GLTX-001 is a biomedicine developed by GoLiver Therapeutics, consisting of an injectable solution made from frozen allogeneic liver cells designed to treat severe liver diseases.
How does the iMillenium™ platform benefit GoLiver Therapeutics?
The iMillenium™ platform provides efficient production capabilities, allowing for the manufacture of billions of liver cells with high yield and cost-effectiveness, which accelerates clinical trials.
What is the GOCLINICALS project?
The GOCLINICALS project aims to clinically assess and confirm the safety and efficacy of GLTX-001 in patients with severe liver failure.
Who are GoLiver Therapeutics’ key partners?
Key partnerships include collaborations with the cell and gene therapy unit at Nantes University Hospital and the Paul-Brousse Hospital, both of which enhance research and clinical development efforts.
What are the future aspirations of GoLiver Therapeutics?
GoLiver Therapeutics plans to diversify its therapeutic offerings and expand innovations in regenerative medicine beyond liver diseases, addressing a range of medical challenges.
